Peritoneal Dialysis Access Associated Infections

Adv Chronic Kidney Dis. 2019 Jan;26(1):23-29. doi: 10.1053/j.ackd.2018.09.002.

Abstract

Infection is a significant driver of morbidity and mortality in patients with end-stage renal disease undergoing maintenance dialysis. In the United States, septicemia and other infections account for 8% deaths in patients undergoing dialysis. In patients undergoing peritoneal dialysis (PD), PD-related peritonitis remains the most frequent treatment-related infection and is the greatest contributor to infection-related morbidity, including risk for hospitalization, and temporary or permanent transfer to hemodialysis. In the 4 decades since the introduction of ambulatory PD in clinical practice, a large number of treatment innovations have been shown to be effective in reducing the risk for exit site infection and PD-related peritonitis. Notwithstanding the evidence for efficacy of these innovations and the numerous adverse health consequences with PD-related peritonitis, the uptake of these interventions in clinical practice around the world remains inconsistent. This article reviews current knowledge with regards to prevention of PD-associated infections, and the diagnosis and management of exit site infections and peritonitis.

Keywords: Dialysis; Exit site infection; Home; Peritoneal; Peritonitis.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Antibiotic Prophylaxis
  • Antifungal Agents / therapeutic use
  • Catheter-Related Infections / diagnosis
  • Catheter-Related Infections / prevention & control*
  • Catheter-Related Infections / therapy
  • Catheterization / methods
  • Humans
  • Injections, Intraperitoneal
  • Kidney Failure, Chronic / therapy*
  • Peritoneal Dialysis / methods*
  • Peritoneal Dialysis, Continuous Ambulatory
  • Peritonitis / diagnosis
  • Peritonitis / prevention & control*
  • Peritonitis / therapy

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents